A non-CME virtual event sponsored by Daiichi Sankyo On Target in FLT3-ITD+ AML: Expert Perspectives on QuANTUM-First. Hear from top experts in your field.

REGISTER NOW

A non-CME virtual event sponsored by Daiichi Sankyo On Target in FLT3-ITD+ AML: Expert Perspectives on QuANTUM-First. Hear from top experts in your field.

REGISTER NOW

VANFLYTA® (quizartinib) logo
  • This site is intended for US healthcare professionals.
  • VANFLYTA REMS
  • Prescribing Information
  • Important Safety Information
  • Contact A Rep
  • For Patients
  • ABOUT
    FLT3-ITD+ AML
    • FLT3-ITD Mutations in AML
    • FLT3 Mutation Testing
    • Evolving Treatment Landscape
  • ABOUT
    VANFLYTA
    • Mechanism of Action
    • FLT3 Selectivity
  • EFFICACY
    • Study Design
    • Overall Survival
    • CR and CRc
    • Duration of CR
    • RFS
  • SAFETY
    • Common Adverse Reactions
    • VANFLYTA REMS
  • DOSING
    • Dosing Snapshot
    • ECG and Electrolyte Monitoring
    • Administration
    • Titration and Dose Modifications
  • NCCN
    GUIDELINES®
  • RESOURCES
    • Access Central
    • Clinical Resources
    • How to Procure VANFLYTA
VANFLYTA® (quizartinib) logo
  • This site is intended for US healthcare professionals.
  • ABOUT FLT3-ITD+ AML
    • FLT3-ITD Mutations in AML
    • FLT3 Mutation Testing
    • Evolving Treatment Landscape
  • ABOUT VANFLYTA
    • Mechanism of Action
    • FLT3 Selectivity
  • EFFICACY
    • Study Design
    • Overall Survival
    • CR and CRc
    • Duration of CR
    • RFS
  • SAFETY
    • Common Adverse Reactions
    • VANFLYTA REMS
  • DOSING
    • Dosing Snapshot
    • ECG and Electrolyte Monitoring
    • Administration
    • Titration and Dose Modifications
  • NCCN GUIDELINES®
  • RESOURCES
    • Access Central
    • Clinical Resources
    • How to Procure VANFLYTA
  • VANFLYTA REMS
  • Prescribing Information
  • Important Safety Information
  • Contact A Rep
  • For Patients

Site Map

Home

About FLT3-ITD+ AML

FLT3-ITD Mutations in AML

FLT3 Mutation Testing

Evolving Treatment Landscape

About VANFLYTA

Mechanism of Action

FLT3 Selectivity

Efficacy

Study Design

Overall Survival

CR and CRc

Duration of CR

RFS

Safety

Common Adverse Reactions

VANFLYTA REMS

Dosing

Dosing Snapshot

ECG and Electrolyte Monitoring

Administration

Titration and Dose Modifications

NCCN Guidelines

Resources

Access Central

Clinical Resources

How to Procure VANFLYTA

VANFLYTA® (quizartinib) logo

This site is intended for US healthcare professionals.

To contact us with questions or concerns about a Daiichi Sankyo product, please call us: 1-877-4DS-PROD (1-877-437-7763).

  • Privacy Policy
  • Terms of Use
  • Contact Us
  • About Daiichi Sankyo
  • Site Map
Daiichi-Sankyo logo

VANFLYTA4U is a program of Daiichi Sankyo AccessCentral4U.
AccessCentral4U™ is a trademark of Daiichi Sankyo Company, Limited.
Trademarks are the property of their respective owners.
VANFLYTA® is a registered trademark of Daiichi Sankyo Company, Limited.
© 2026 Daiichi Sankyo, Inc. PP-US-VN-0884-2 03/26

You are leaving VANFLYTAHCP.com

The site you are linking to is not controlled or endorsed by Daiichi-Sankyo, and we are not responsible for the content.

Thank you for visiting.

CANCEL OK
Back to Top